Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20223262 | 0.91 | NAAA (0.49) | NAAAPIK3CDALOX5CYP1A2 | |
| SCHEMBL21166299 | 0.91 | NAAA (0.49) | NAAAPIK3CDALOX5CYP1A2 | |
| SCHEMBL18505908 | 0.91 | NAAA (0.49) | NAAAPIK3CDALOX5CYP1A2 | |
| SCHEMBL24850722 | 0.89 | NAAA (0.48) | NAAAPIK3CDCYP1A2 | |
| SCHEMBL24909681 | 0.89 | NAAA (0.48) | NAAAPIK3CDCYP1A2 | |
| SCHEMBL23594586 | 0.85 | NAAA (0.47) | NAAAPIK3CDCYP1A2 | |
| SCHEMBL25850315 | 0.84 | PIK3CD (0.50) | NAAAPIK3CDCYP1A2 | |
| SCHEMBL24851104 | 0.78 | NAAA (0.49) | NAAAPIK3CDALOX5CYP1A2 | |
| SCHEMBL21922559 | 0.76 | ALOX5 (0.41) | PIK3CDALOX5 | |
| SCHEMBL18799294 | 0.76 | ALOX5 (0.41) | PIK3CDALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | NAAA 2737/4885PIK3CD 897/4885ALOX5 2813/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | NAAA 2737/4885PIK3CD 897/4885ALOX5 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.